Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

999712

registered interest
date	01/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	IVF
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 01 November 2018 to Question 185122 on In Vitro Fertilisation, if he will make an assessment of the potential merits of making mandatory National Institute for Health and Care Excellence guidelines on the assessment and treatment of people with fertility problems.
tabling member constituency	Oxford West and Abingdon
tabling member printed	Layla Moran
uin	187136
answer	answer is ministerial correction date of answer 06/11/2018 answer text <p>We have no such plans. The National Institute for Health and Care Excellence’s clinical guidelines help healthcare professionals deliver the best possible care based on the best available evidence. They focus on aspects of healthcare that are commissioned locally.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 06/11/2018 11:17:11 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4656 label Biography information for Layla Moran

997248

registered interest
date	29/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	IVF
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that Clinical Commissioning Groups meet guidelines that IVF should be offered to women until age 42; what estimate he has made of the number of Clinical Commissioning Groups that do not meet these guidelines; and if he will make a statement.
tabling member constituency	Oxford West and Abingdon
tabling member printed	Layla Moran
uin	185122
answer	answer is ministerial correction date of answer 01/11/2018 answer text <p>Clinical commissioning groups (CCGs) should have regard to the National Institute for Health and Care Excellence (NICE) guideline on the assessment and treatment of people with fertility problems when commissioning services for which they are responsible. This includes the recommendation in the guideline that three cycles of in-vitro fertilisation be offered to qualifying couples where the woman is under the age of 40 and one cycle where the woman is between the ages of 40 and 42.</p><p> </p><p>The NICE guideline is evidence based best practice for clinicians but is not mandatory. The availability of National Health Service funded fertility treatment is matter for local determination. Decisions on the level of service provision are underpinned by clinical insight and knowledge of local healthcare needs and priorities.</p><p> </p><p>Information about the commissioning of fertility services is not collected centrally but an annual survey is undertaken by Fertility Fairness. This can be found at the following link:</p><p> </p><p><a href="http://www.fertilityfairness.co.uk/wp-content/uploads/2018/10/England-FertilityFairness_FOI_2018.pdf" target="_blank">http://www.fertilityfairness.co.uk/wp-content/uploads/2018/10/England-FertilityFairness_FOI_2018.pdf</a></p><p> </p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 01/11/2018 16:52:39 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4656 label Biography information for Layla Moran

994276

registered interest
date	24/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ovarian Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to (a) improve public awareness of ovarian cancer and its symptoms, (b) increase early diagnosis rates and (c) increase access to treatment in specialist centres in (i) Oxfordshire and (ii) England.
tabling member constituency	Oxford West and Abingdon
tabling member printed	Layla Moran
uin	183497
answer	answer is ministerial correction date of answer 29/10/2018 answer text <p>Public Health England has run a number of “Be Clear on Cancer” (BCOC) campaigns to help improve earlier diagnosis. In 2014, BCOC conducted a regional ovarian cancer campaign and in 2017, a pilot which focussed on a range of abdominal symptoms, such as diarrhoea, bloating and discomfort that can be indicative of a number of cancers, including ovarian cancer. Decisions on which cancers the BCOC campaigns should focus on are informed by a steering group and the outcomes of the regional and pilot campaigns will be considered for 2019/20.</p><p> </p><p>Nationally, NHS England is testing innovative ways of diagnosing cancer earlier, with sites piloting multi-disciplinary diagnostic centres for patients with vague or non-specific symptoms. The pilots are taking place in London, Greater Manchester, Leeds, Bristol, Oxfordshire and Airedale, Wharfedale and Craven (Yorkshire). The Prime Minister’s October 2018 announcement pledged to roll out these rapid diagnostic centres across the country to offer patients a range of tests in the same day with rapid access to results. The centres will help make a huge improvement in early diagnosis.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/10/2018 17:54:43 answering member 4067 label Biography information for Steve Brine
tabling member	4656 label Biography information for Layla Moran

990345

registered interest
date	18/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gender Dysphoria: Clinics
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce waiting times for gender identity clinics.
tabling member constituency	Oxford West and Abingdon
tabling member printed	Layla Moran
uin	181320
answer	answer is ministerial correction date of answer 23/10/2018 answer text <p>Following public consultation, NHS England published new service specification<sup>1 </sup>for specialised gender dysphoria services in September 2018. The new service specifications will be used in a national process of procurement later in the year that will determine which organisations are best able to deliver gender dysphoria services from 2019/20. The new specifications also describe that in order to increase clinical capacity to meet increasing demand, and thereby reduce waiting lists over time, new models for delivery will be explored.</p><p> </p><p> </p><p>Note:</p><p> </p><p><sup>1</sup><a href="https://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-e/e10/" target="_blank">https://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-e/e10/</a></p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay question first answered 23/10/2018 16:29:01 answering member 4095 label Biography information for Steve Barclay
tabling member	4656 label Biography information for Layla Moran

984869

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Department of Health and Social Care: Northern Ireland
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and which (a) Ministers and (b) officials in his Department have visited the Irish border in the last 12 months; when those visits took place; and how long they spent at the border in each of those visits.
tabling member constituency	Oxford West and Abingdon
tabling member printed	Layla Moran
uin	177815
answer	answer is ministerial correction date of answer 18/10/2018 answer text <p>There have been no visits to the Irish border by Ministers or officials at the Department in the last 12 months.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 18/10/2018 11:17:47 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4656 label Biography information for Layla Moran

982970

registered interest
date	08/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Allergies: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the shortage of EpiPen 0.3mg Auto-Injectors in (a) Oxfordshire and (b) England; and what steps he is taking to address that shortage.
tabling member constituency	Oxford West and Abingdon
tabling member printed	Layla Moran
uin	176640
answer	answer is ministerial correction date of answer 16/10/2018 answer text <p>The United Kingdom supplier of EpiPen 0.3mg adrenaline auto-injectors, Mylan, has estimated that they are currently able to supply approximately 50% of their normal demand for this product. Within the UK there are two alternative 0.3mg adrenaline auto-injector devices and the manufacturers of these have been able to increase their supplies and support the market during this time. We therefore expect that patients will continue to be able to access 0.3mg adrenaline auto-injector devices if prescribed. The Department is working very closely with all the manufacturers of adrenaline auto-injectors, the Medicines and Healthcare products Regulatory Agency, NHS England, and others to try to resolve these issues and improve the situation as quickly as possible.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/10/2018 16:55:36 answering member 4067 label Biography information for Steve Brine
tabling member	4656 label Biography information for Layla Moran

972475

registered interest
date	12/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Paediatric Autoimmune Neuropsychiatric Disorders
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to improve (a) diagnosis and (b) treatment of paediatric autoimmune neuropsychiatric disease.
tabling member constituency	Oxford West and Abingdon
tabling member printed	Layla Moran
uin	174146
answer	answer is ministerial correction date of answer 10/10/2018 answer text <p>Paediatric autoimmune neuropsychiatric disease (PANDAS) is currently a research and clinical area of interest for professionals working with children and young people. There is evidence that exposure to an infection can act as a trigger for some children to present acutely with a range of neurodevelopmental and mental health symptoms such as tics, obsessive compulsive disorder, attention deficit hyperactivity disorder and eating problems etc.</p><p> </p><p>However, there is inconclusive research evidence to demonstrate that PANDAS is a discrete disease entity. It is therefore not listed as a diagnosis by the International Statistical Classification of Diseases and Related Health Problems or the Diagnostic and Statistical Manual of Mental Disorders.</p> answering member constituency West Suffolk answering member printed Matt Hancock question first answered 10/10/2018 12:58:06 answering member 4070 label Biography information for Matt Hancock previous answer version 77322 answering member constituency West Suffolk answering member printed Matt Hancock answering member 4070 label Biography information for Matt Hancock
tabling member	4656 label Biography information for Layla Moran

972478

registered interest
date	12/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Everolimus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to improve access to Everolimus for patients with epilepsy related to tuberous sclerosis complex.
tabling member constituency	Oxford West and Abingdon
tabling member printed	Layla Moran
uin	174147
answer	answer is ministerial correction date of answer 09/10/2018 answer text <p>Everolimus in the treatment of refractory epilepsy associated with tuberous sclerosis complex has been through the NHS England clinical policy development process and was considered by the Clinical Priorities Advisory Group (CPAG) as part of the May 2018 prioritisation round. CPAG determined that the treatment fell into the lower end of five levels of relative priority for funding, and therefore the decision has been taken to not routinely commission the treatment at this time.</p><p> </p><p>Everolimus will be considered again at the next prioritisation round in November and, should it be successful, funding would be made available from April 2019. One factor that can significantly influence the relative priority of a treatment is the price put forward by the manufacturer. In advance of Everolimus being considered again in November, the manufacturer has been given the opportunity to offer a revised price and submit any further evidence that may have become available since the last prioritisation round.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/10/2018 16:58:49 answering member 4067 label Biography information for Steve Brine
tabling member	4656 label Biography information for Layla Moran

964671

registered interest
date	03/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	IVF
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of Clinical Commissioning Groups that do not meet NICE guidelines for IVF treatment; and what steps he is taking to encourage those Groups to adhere to those guidelines.
tabling member constituency	Oxford West and Abingdon
tabling member printed	Layla Moran
uin	169808
answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The Department does not collect official data on this subject matter. However, the national stakeholder organisation, Fertility Fairness, undertakes an annual survey using Freedom of Information requests directly from clinical commissioning groups (CCGs). Information collected for 2016/17 shows that 18 CCGs offer three cycles of in vitro fertilisation (IVF), in line with the current National Institute for Health and Care Excellence (NICE) fertility guidelines. Of the remaining CCGs that have not implemented the guidance in full 50 CCGs offer two cycles of IVF, 137 offer one cycle, and seven offer no routine service.</p><p> </p><p>The Government’s position that CCGs should be following the NICE fertility guidelines as part of their NHS services to local people. I plan to meet with officials from NHS England and the Human Fertilisation and Embryology Authority shortly to discuss NHS commissioning of fertility services and what more might be done to support CCGs to improve their service offer.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 169809 question first answered 11/09/2018 16:08:36 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4656 label Biography information for Layla Moran

964672

registered interest
date	03/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Fertility: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent discussions his Department has held with NHS England on the commissioning of fertility services.
tabling member constituency	Oxford West and Abingdon
tabling member printed	Layla Moran
uin	169809
answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The Department does not collect official data on this subject matter. However, the national stakeholder organisation, Fertility Fairness, undertakes an annual survey using Freedom of Information requests directly from clinical commissioning groups (CCGs). Information collected for 2016/17 shows that 18 CCGs offer three cycles of in vitro fertilisation (IVF), in line with the current National Institute for Health and Care Excellence (NICE) fertility guidelines. Of the remaining CCGs that have not implemented the guidance in full 50 CCGs offer two cycles of IVF, 137 offer one cycle, and seven offer no routine service.</p><p> </p><p>The Government’s position that CCGs should be following the NICE fertility guidelines as part of their NHS services to local people. I plan to meet with officials from NHS England and the Human Fertilisation and Embryology Authority shortly to discuss NHS commissioning of fertility services and what more might be done to support CCGs to improve their service offer.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 169808 question first answered 11/09/2018 16:08:36 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4656 label Biography information for Layla Moran